PACCE Results: Poorer Outcomes When Panitumumab is Added to Chemotherapy and Avastin

Patients being treated for the first time with chemotherapy and Avastin® (bevacizumab) do worse if Vectibix™ (panitumumab) is added to their chemotherapy.  Median time until the cancer progresses is shorter, and they have more serious side effects. KRAS status made no difference.  Both patients with wild-type and mutated KRAS in their tumors had worse outcomes when…  Read More

Preventive Measures Reduce Rash from Vectibix

Nearly all patients who are treated with Vectibix™ (panitumumab) will develop an itchy skin rash that looks something like acne.  However, treating the rash preemptively  before it appears reduces its severity and lengthens the time before more serious rash appears. During the STEPP (Skin Toxicity Evaluation Protocol with Panitumumab) trial, researchers randomized patients who were being…  Read More

Is KRAS Testing Right for You?

Concerned about whether you should have your tumor tested for a KRAS mutation? You should discuss KRAS testing and your treatment options with your doctor If you are currently being treated with Erbitux® (cetuximab) or Vectibix™ (panitumumab) for colorectal cancer. Before beginning Erbitux or Vectibix treatment, either as single medicines or in combination with chemotherapy. When…  Read More